151 related articles for article (PubMed ID: 1711915)
1. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
Seiffert D; Mimuro J; Schleef RR; Loskutoff DJ
Cell Differ Dev; 1990 Dec; 32(3):287-92. PubMed ID: 1711915
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
[TBL] [Abstract][Full Text] [Related]
3. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
Ehrlich HJ; Gebbink RK; Preissner KT; Keijer J; Esmon NL; Mertens K; Pannekoek H
J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
[TBL] [Abstract][Full Text] [Related]
4. Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin.
Owensby DA; Morton PA; Wun TC; Schwartz AL
J Biol Chem; 1991 Mar; 266(7):4334-40. PubMed ID: 1705551
[TBL] [Abstract][Full Text] [Related]
5. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
[TBL] [Abstract][Full Text] [Related]
6. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
7. Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue.
Kirchheimer JC; Binder BR; Remold HG
J Immunol; 1990 Sep; 145(5):1518-22. PubMed ID: 1696600
[TBL] [Abstract][Full Text] [Related]
8. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
[TBL] [Abstract][Full Text] [Related]
9. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor.
Seiffert D; Wagner NN; Loskutoff DJ
J Cell Biol; 1990 Sep; 111(3):1283-91. PubMed ID: 1697297
[TBL] [Abstract][Full Text] [Related]
10. Production of proteases type plasminogen activator and their inhibitor in cornea.
Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
[TBL] [Abstract][Full Text] [Related]
11. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells.
Mimuro J; Loskutoff DJ
J Biol Chem; 1989 Mar; 264(9):5058-63. PubMed ID: 2494180
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon.
Niedbala MJ; Picarella MS
Blood; 1992 Feb; 79(3):678-87. PubMed ID: 1732009
[TBL] [Abstract][Full Text] [Related]
13. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
14. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
15. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
16. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.
Schleef RR; Podor TJ; Dunne E; Mimuro J; Loskutoff DJ
J Cell Biol; 1990 Jan; 110(1):155-63. PubMed ID: 2104856
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells.
Hagège J; Peraldi MN; Rondeau E; Adida C; Delarue F; Medcalf R; Schleuning WD; Sraer JD
Am J Pathol; 1992 Jul; 141(1):117-28. PubMed ID: 1632457
[TBL] [Abstract][Full Text] [Related]
18. Matrix plasminogen activator inhibitor. Modulation of the extracellular proteolytic environment.
Knudsen BS; Nachman RL
J Biol Chem; 1988 Jul; 263(19):9476-81. PubMed ID: 2967824
[TBL] [Abstract][Full Text] [Related]
19. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells.
Moser TL; Enghild JJ; Pizzo SV; Stack MS
Biochem J; 1995 May; 307 ( Pt 3)(Pt 3):867-73. PubMed ID: 7537960
[TBL] [Abstract][Full Text] [Related]
20. Collagen modulates gene activation of plasminogen activator system molecules.
Jones JM; Cohen RL; Chambers DA
Exp Cell Res; 2002 Nov; 280(2):244-54. PubMed ID: 12413890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]